> top > projects > spacy-test > docs > PubMed:3922282 > annotations
spacy-test Home  

PubMed:3922282 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
spaCy_T0 0-11 NN denotes gamma-Vinyl
spaCy_T1 12-16 NNP denotes GABA
spaCy_T2 16-17 : denotes :
spaCy_T3 18-19 DT denotes a
spaCy_T4 20-32 JJ denotes double-blind
spaCy_T5 33-51 JJ denotes placebo-controlled
spaCy_T6 52-57 NN denotes trial
spaCy_T7 58-60 IN denotes in
spaCy_T8 61-68 JJ denotes partial
spaCy_T9 69-77 NN denotes epilepsy
spaCy_T10 77-78 . denotes .
spaCy_T11 79-82 DT denotes The
spaCy_T12 83-96 JJ denotes antiepileptic
spaCy_T13 97-103 NN denotes effect
spaCy_T14 104-106 IN denotes of
spaCy_T15 107-118 NN denotes gamma-vinyl
spaCy_T16 119-137 JJ denotes gamma-aminobutyric
spaCy_T17 138-142 NN denotes acid
spaCy_T18 143-144 -LRB- denotes (
spaCy_T19 144-148 NNP denotes GABA
spaCy_T20 148-149 -RRB- denotes )
spaCy_T21 149-150 , denotes ,
spaCy_T22 151-153 DT denotes an
spaCy_T23 154-166 JJ denotes irreversible
spaCy_T24 167-184 JJ denotes GABA-transaminase
spaCy_T25 185-194 NN denotes inhibitor
spaCy_T26 194-195 , denotes ,
spaCy_T27 196-199 VBD denotes was
spaCy_T28 200-212 VBN denotes investigated
spaCy_T29 213-215 IN denotes in
spaCy_T30 216-218 DT denotes an
spaCy_T31 219-225 JJ denotes add-on
spaCy_T32 225-226 , denotes ,
spaCy_T33 227-245 JJ denotes placebo-controlled
spaCy_T34 245-246 , denotes ,
spaCy_T35 247-259 JJ denotes double-blind
spaCy_T36 259-260 , denotes ,
spaCy_T37 261-271 JJ denotes cross-over
spaCy_T38 271-272 , denotes ,
spaCy_T39 273-283 JJ denotes fixed-dose
spaCy_T40 284-289 NN denotes trial
spaCy_T41 289-290 . denotes .
spaCy_T42 291-301 CD denotes Twenty-one
spaCy_T43 302-310 NNS denotes patients
spaCy_T44 311-320 VBG denotes suffering
spaCy_T45 321-325 IN denotes from
spaCy_T46 326-335 JJ denotes difficult
spaCy_T47 336-338 TO denotes to
spaCy_T48 339-346 VB denotes control
spaCy_T49 347-354 JJ denotes complex
spaCy_T50 355-362 JJ denotes partial
spaCy_T51 363-371 NNS denotes seizures
spaCy_T52 372-384 VBD denotes participated
spaCy_T53 384-385 : denotes ;
spaCy_T54 386-388 CD denotes 18
spaCy_T55 389-397 NNS denotes patients
spaCy_T56 398-407 VBD denotes completed
spaCy_T57 408-411 DT denotes the
spaCy_T58 412-417 NN denotes trial
spaCy_T59 417-418 . denotes .
spaCy_T60 419-424 NNP denotes Serum
spaCy_T61 425-431 NNS denotes levels
spaCy_T62 432-434 IN denotes of
spaCy_T63 435-446 JJ denotes concomitant
spaCy_T64 447-460 JJ denotes antiepileptic
spaCy_T65 461-466 NNS denotes drugs
spaCy_T66 467-471 VBD denotes were
spaCy_T67 472-476 VBN denotes kept
spaCy_T68 477-485 JJ denotes constant
spaCy_T69 486-496 IN denotes throughout
spaCy_T70 497-500 DT denotes the
spaCy_T71 501-506 NN denotes trial
spaCy_T72 506-507 . denotes .
spaCy_T73 508-513 CD denotes Three
spaCy_T74 514-522 NNS denotes patients
spaCy_T75 523-524 -LRB- denotes (
spaCy_T76 524-526 CD denotes 17
spaCy_T77 526-527 NN denotes %
spaCy_T78 527-528 -RRB- denotes )
spaCy_T79 529-540 VBD denotes experienced
spaCy_T80 541-542 DT denotes a
spaCy_T81 543-545 CD denotes 75
spaCy_T82 545-546 NN denotes %
spaCy_T83 547-556 NN denotes reduction
spaCy_T84 557-559 IN denotes in
spaCy_T85 560-567 NN denotes seizure
spaCy_T86 568-577 NN denotes frequency
spaCy_T87 578-581 CC denotes and
spaCy_T88 582-584 IN denotes in
spaCy_T89 585-586 CD denotes 8
spaCy_T90 587-588 -LRB- denotes (
spaCy_T91 588-590 CD denotes 44
spaCy_T92 590-591 NN denotes %
spaCy_T93 591-592 -RRB- denotes )
spaCy_T94 593-596 DT denotes the
spaCy_T95 597-605 NNS denotes seizures
spaCy_T96 606-610 VBD denotes were
spaCy_T97 611-618 VBN denotes reduced
spaCy_T98 619-621 IN denotes by
spaCy_T99 622-624 IN denotes at
spaCy_T100 625-630 JJS denotes least
spaCy_T101 631-633 CD denotes 50
spaCy_T102 633-634 NN denotes %
spaCy_T103 634-635 . denotes .
spaCy_T104 636-639 CD denotes Two
spaCy_T105 640-648 NNS denotes patients
spaCy_T106 649-658 VBD denotes developed
spaCy_T107 659-660 DT denotes a
spaCy_T108 661-669 JJ denotes moderate
spaCy_T109 670-673 CC denotes and
spaCy_T110 674-675 CD denotes 1
spaCy_T111 676-683 NN denotes patient
spaCy_T112 684-685 DT denotes a
spaCy_T113 686-692 JJ denotes marked
spaCy_T114 693-701 NN denotes increase
spaCy_T115 702-704 IN denotes in
spaCy_T116 705-712 NN denotes seizure
spaCy_T117 713-722 NN denotes frequency
spaCy_T118 723-729 IN denotes during
spaCy_T119 730-739 NN denotes treatment
spaCy_T120 740-744 IN denotes with
spaCy_T121 745-756 NN denotes gamma-vinyl
spaCy_T122 757-761 NNP denotes GABA
spaCy_T123 761-762 . denotes .
spaCy_T124 763-769 IN denotes Except
spaCy_T125 770-773 IN denotes for
spaCy_T126 774-775 CD denotes 2
spaCy_T127 776-784 NNS denotes patients
spaCy_T128 785-788 WP denotes who
spaCy_T129 789-792 VBD denotes had
spaCy_T130 793-795 TO denotes to
spaCy_T131 796-807 VB denotes discontinue
spaCy_T132 808-811 DT denotes the
spaCy_T133 812-817 NN denotes trial
spaCy_T134 818-825 IN denotes because
spaCy_T135 826-828 IN denotes of
spaCy_T136 829-836 JJ denotes adverse
spaCy_T137 837-844 NNS denotes effects
spaCy_T138 845-847 IN denotes of
spaCy_T139 848-859 NN denotes gamma-vinyl
spaCy_T140 860-864 NNP denotes GABA
spaCy_T141 864-865 , denotes ,
spaCy_T142 866-869 DT denotes the
spaCy_T143 870-882 NNS denotes participants
spaCy_T144 883-887 VBD denotes were
spaCy_T145 888-894 JJ denotes unable
spaCy_T146 895-897 TO denotes to
spaCy_T147 898-910 JJ denotes discriminate
spaCy_T148 911-918 IN denotes between
spaCy_T149 919-928 NN denotes treatment
spaCy_T150 929-937 VBZ denotes regimens
spaCy_T151 938-942 IN denotes with
spaCy_T152 943-949 NN denotes regard
spaCy_T153 950-952 TO denotes to
spaCy_T154 953-957 VB denotes side
spaCy_T155 958-965 NNS denotes effects
spaCy_T156 965-966 . denotes .
spaCy_T157 967-978 NN denotes gamma-vinyl
spaCy_T158 979-983 NNP denotes GABA
spaCy_T159 984-989 VBZ denotes seems
spaCy_T160 990-992 TO denotes to
spaCy_T161 993-995 VB denotes be
spaCy_T162 996-997 DT denotes a
spaCy_T163 998-1007 JJ denotes promising
spaCy_T164 1008-1011 JJ denotes new
spaCy_T165 1012-1025 JJ denotes antiepileptic
spaCy_T166 1026-1030 NN denotes drug
spaCy_T167 1030-1031 , denotes ,
spaCy_T168 1032-1035 CC denotes and
spaCy_T169 1036-1039 DT denotes the
spaCy_T170 1040-1045 JJ denotes first
spaCy_T171 1046-1049 CD denotes one
spaCy_T172 1050-1052 TO denotes to
spaCy_T173 1053-1060 VB denotes present
spaCy_T174 1061-1071 JJ denotes convincing
spaCy_T175 1072-1080 NN denotes evidence
spaCy_T176 1081-1083 IN denotes of
spaCy_T177 1084-1085 DT denotes a
spaCy_T178 1086-1095 JJ denotes GABAergic
spaCy_T179 1096-1105 NN denotes mechanism
spaCy_T180 1106-1108 IN denotes of
spaCy_T181 1109-1115 NN denotes action
spaCy_T182 1115-1116 . denotes .
spaCy_R0 spaCy_T0 spaCy_T1 compound gamma-Vinyl,GABA
spaCy_R1 spaCy_T1 spaCy_T1 ROOT GABA,GABA
spaCy_R10 spaCy_T10 spaCy_T1 punct .,GABA
spaCy_R100 spaCy_T100 spaCy_T101 advmod least,50
spaCy_R101 spaCy_T101 spaCy_T102 nummod 50,%
spaCy_R102 spaCy_T102 spaCy_T98 pobj %,by
spaCy_R103 spaCy_T103 spaCy_T79 punct .,experienced
spaCy_R104 spaCy_T104 spaCy_T105 nummod Two,patients
spaCy_R105 spaCy_T105 spaCy_T106 nsubj patients,developed
spaCy_R106 spaCy_T106 spaCy_T106 ROOT developed,developed
spaCy_R107 spaCy_T107 spaCy_T111 det a,patient
spaCy_R108 spaCy_T108 spaCy_T111 amod moderate,patient
spaCy_R109 spaCy_T109 spaCy_T108 cc and,moderate
spaCy_R11 spaCy_T11 spaCy_T13 det The,effect
spaCy_R110 spaCy_T110 spaCy_T111 nummod 1,patient
spaCy_R111 spaCy_T111 spaCy_T106 dobj patient,developed
spaCy_R112 spaCy_T112 spaCy_T114 det a,increase
spaCy_R113 spaCy_T113 spaCy_T114 amod marked,increase
spaCy_R114 spaCy_T114 spaCy_T106 dobj increase,developed
spaCy_R115 spaCy_T115 spaCy_T114 prep in,increase
spaCy_R116 spaCy_T116 spaCy_T117 compound seizure,frequency
spaCy_R117 spaCy_T117 spaCy_T115 pobj frequency,in
spaCy_R118 spaCy_T118 spaCy_T114 prep during,increase
spaCy_R119 spaCy_T119 spaCy_T118 pobj treatment,during
spaCy_R12 spaCy_T12 spaCy_T13 amod antiepileptic,effect
spaCy_R120 spaCy_T120 spaCy_T119 prep with,treatment
spaCy_R121 spaCy_T121 spaCy_T122 compound gamma-vinyl,GABA
spaCy_R122 spaCy_T122 spaCy_T120 pobj GABA,with
spaCy_R123 spaCy_T123 spaCy_T106 punct .,developed
spaCy_R124 spaCy_T124 spaCy_T144 prep Except,were
spaCy_R125 spaCy_T125 spaCy_T124 prep for,Except
spaCy_R126 spaCy_T126 spaCy_T127 nummod 2,patients
spaCy_R127 spaCy_T127 spaCy_T125 pobj patients,for
spaCy_R128 spaCy_T128 spaCy_T129 nsubj who,had
spaCy_R129 spaCy_T129 spaCy_T127 relcl had,patients
spaCy_R13 spaCy_T13 spaCy_T28 nsubjpass effect,investigated
spaCy_R130 spaCy_T130 spaCy_T131 aux to,discontinue
spaCy_R131 spaCy_T131 spaCy_T129 xcomp discontinue,had
spaCy_R132 spaCy_T132 spaCy_T133 det the,trial
spaCy_R133 spaCy_T133 spaCy_T131 dobj trial,discontinue
spaCy_R134 spaCy_T134 spaCy_T131 prep because,discontinue
spaCy_R135 spaCy_T135 spaCy_T134 pcomp of,because
spaCy_R136 spaCy_T136 spaCy_T137 amod adverse,effects
spaCy_R137 spaCy_T137 spaCy_T134 pobj effects,because
spaCy_R138 spaCy_T138 spaCy_T137 prep of,effects
spaCy_R139 spaCy_T139 spaCy_T140 compound gamma-vinyl,GABA
spaCy_R14 spaCy_T14 spaCy_T13 prep of,effect
spaCy_R140 spaCy_T140 spaCy_T138 pobj GABA,of
spaCy_R141 spaCy_T141 spaCy_T144 punct ",",were
spaCy_R142 spaCy_T142 spaCy_T143 det the,participants
spaCy_R143 spaCy_T143 spaCy_T144 nsubj participants,were
spaCy_R144 spaCy_T144 spaCy_T144 ROOT were,were
spaCy_R145 spaCy_T145 spaCy_T144 acomp unable,were
spaCy_R146 spaCy_T146 spaCy_T147 aux to,discriminate
spaCy_R147 spaCy_T147 spaCy_T145 xcomp discriminate,unable
spaCy_R148 spaCy_T148 spaCy_T147 prep between,discriminate
spaCy_R149 spaCy_T149 spaCy_T150 compound treatment,regimens
spaCy_R15 spaCy_T15 spaCy_T17 nmod gamma-vinyl,acid
spaCy_R150 spaCy_T150 spaCy_T148 pobj regimens,between
spaCy_R151 spaCy_T151 spaCy_T147 prep with,discriminate
spaCy_R152 spaCy_T152 spaCy_T151 pobj regard,with
spaCy_R153 spaCy_T153 spaCy_T152 prep to,regard
spaCy_R154 spaCy_T154 spaCy_T155 compound side,effects
spaCy_R155 spaCy_T155 spaCy_T153 pobj effects,to
spaCy_R156 spaCy_T156 spaCy_T144 punct .,were
spaCy_R157 spaCy_T157 spaCy_T158 compound gamma-vinyl,GABA
spaCy_R158 spaCy_T158 spaCy_T159 nsubj GABA,seems
spaCy_R159 spaCy_T159 spaCy_T159 ROOT seems,seems
spaCy_R16 spaCy_T16 spaCy_T17 amod gamma-aminobutyric,acid
spaCy_R160 spaCy_T160 spaCy_T161 aux to,be
spaCy_R161 spaCy_T161 spaCy_T159 xcomp be,seems
spaCy_R162 spaCy_T162 spaCy_T166 det a,drug
spaCy_R163 spaCy_T163 spaCy_T166 amod promising,drug
spaCy_R164 spaCy_T164 spaCy_T166 amod new,drug
spaCy_R165 spaCy_T165 spaCy_T166 amod antiepileptic,drug
spaCy_R166 spaCy_T166 spaCy_T161 attr drug,be
spaCy_R167 spaCy_T167 spaCy_T159 punct ",",seems
spaCy_R168 spaCy_T168 spaCy_T159 cc and,seems
spaCy_R169 spaCy_T169 spaCy_T171 det the,one
spaCy_R17 spaCy_T17 spaCy_T14 pobj acid,of
spaCy_R170 spaCy_T170 spaCy_T171 amod first,one
spaCy_R171 spaCy_T171 spaCy_T159 conj one,seems
spaCy_R172 spaCy_T172 spaCy_T173 aux to,present
spaCy_R173 spaCy_T173 spaCy_T171 relcl present,one
spaCy_R174 spaCy_T174 spaCy_T175 amod convincing,evidence
spaCy_R175 spaCy_T175 spaCy_T173 dobj evidence,present
spaCy_R176 spaCy_T176 spaCy_T175 prep of,evidence
spaCy_R177 spaCy_T177 spaCy_T179 det a,mechanism
spaCy_R178 spaCy_T178 spaCy_T179 amod GABAergic,mechanism
spaCy_R179 spaCy_T179 spaCy_T176 pobj mechanism,of
spaCy_R18 spaCy_T18 spaCy_T17 punct (,acid
spaCy_R180 spaCy_T180 spaCy_T179 prep of,mechanism
spaCy_R181 spaCy_T181 spaCy_T180 pobj action,of
spaCy_R182 spaCy_T182 spaCy_T159 punct .,seems
spaCy_R19 spaCy_T19 spaCy_T17 appos GABA,acid
spaCy_R2 spaCy_T2 spaCy_T1 punct :,GABA
spaCy_R20 spaCy_T20 spaCy_T17 punct ),acid
spaCy_R21 spaCy_T21 spaCy_T17 punct ",",acid
spaCy_R22 spaCy_T22 spaCy_T25 det an,inhibitor
spaCy_R23 spaCy_T23 spaCy_T25 amod irreversible,inhibitor
spaCy_R24 spaCy_T24 spaCy_T25 amod GABA-transaminase,inhibitor
spaCy_R25 spaCy_T25 spaCy_T13 appos inhibitor,effect
spaCy_R26 spaCy_T26 spaCy_T28 punct ",",investigated
spaCy_R27 spaCy_T27 spaCy_T28 auxpass was,investigated
spaCy_R28 spaCy_T28 spaCy_T28 ROOT investigated,investigated
spaCy_R29 spaCy_T29 spaCy_T28 prep in,investigated
spaCy_R3 spaCy_T3 spaCy_T6 det a,trial
spaCy_R30 spaCy_T30 spaCy_T40 det an,trial
spaCy_R31 spaCy_T31 spaCy_T40 amod add-on,trial
spaCy_R32 spaCy_T32 spaCy_T40 punct ",",trial
spaCy_R33 spaCy_T33 spaCy_T40 amod placebo-controlled,trial
spaCy_R34 spaCy_T34 spaCy_T40 punct ",",trial
spaCy_R35 spaCy_T35 spaCy_T40 amod double-blind,trial
spaCy_R36 spaCy_T36 spaCy_T40 punct ",",trial
spaCy_R37 spaCy_T37 spaCy_T40 amod cross-over,trial
spaCy_R38 spaCy_T38 spaCy_T40 punct ",",trial
spaCy_R39 spaCy_T39 spaCy_T40 amod fixed-dose,trial
spaCy_R4 spaCy_T4 spaCy_T6 amod double-blind,trial
spaCy_R40 spaCy_T40 spaCy_T29 pobj trial,in
spaCy_R41 spaCy_T41 spaCy_T28 punct .,investigated
spaCy_R42 spaCy_T42 spaCy_T43 nummod Twenty-one,patients
spaCy_R43 spaCy_T43 spaCy_T52 nsubj patients,participated
spaCy_R44 spaCy_T44 spaCy_T43 acl suffering,patients
spaCy_R45 spaCy_T45 spaCy_T44 prep from,suffering
spaCy_R46 spaCy_T46 spaCy_T45 pcomp difficult,from
spaCy_R47 spaCy_T47 spaCy_T48 aux to,control
spaCy_R48 spaCy_T48 spaCy_T44 advcl control,suffering
spaCy_R49 spaCy_T49 spaCy_T51 amod complex,seizures
spaCy_R5 spaCy_T5 spaCy_T6 amod placebo-controlled,trial
spaCy_R50 spaCy_T50 spaCy_T51 amod partial,seizures
spaCy_R51 spaCy_T51 spaCy_T48 dobj seizures,control
spaCy_R52 spaCy_T52 spaCy_T52 ROOT participated,participated
spaCy_R53 spaCy_T53 spaCy_T52 punct ;,participated
spaCy_R54 spaCy_T54 spaCy_T55 nummod 18,patients
spaCy_R55 spaCy_T55 spaCy_T56 nsubj patients,completed
spaCy_R56 spaCy_T56 spaCy_T52 conj completed,participated
spaCy_R57 spaCy_T57 spaCy_T58 det the,trial
spaCy_R58 spaCy_T58 spaCy_T56 dobj trial,completed
spaCy_R59 spaCy_T59 spaCy_T56 punct .,completed
spaCy_R6 spaCy_T6 spaCy_T1 appos trial,GABA
spaCy_R60 spaCy_T60 spaCy_T61 compound Serum,levels
spaCy_R61 spaCy_T61 spaCy_T67 nsubjpass levels,kept
spaCy_R62 spaCy_T62 spaCy_T61 prep of,levels
spaCy_R63 spaCy_T63 spaCy_T65 amod concomitant,drugs
spaCy_R64 spaCy_T64 spaCy_T65 amod antiepileptic,drugs
spaCy_R65 spaCy_T65 spaCy_T62 pobj drugs,of
spaCy_R66 spaCy_T66 spaCy_T67 auxpass were,kept
spaCy_R67 spaCy_T67 spaCy_T67 ROOT kept,kept
spaCy_R68 spaCy_T68 spaCy_T67 oprd constant,kept
spaCy_R69 spaCy_T69 spaCy_T67 prep throughout,kept
spaCy_R7 spaCy_T7 spaCy_T6 prep in,trial
spaCy_R70 spaCy_T70 spaCy_T71 det the,trial
spaCy_R71 spaCy_T71 spaCy_T69 pobj trial,throughout
spaCy_R72 spaCy_T72 spaCy_T67 punct .,kept
spaCy_R73 spaCy_T73 spaCy_T74 nummod Three,patients
spaCy_R74 spaCy_T74 spaCy_T79 nsubj patients,experienced
spaCy_R75 spaCy_T75 spaCy_T74 punct (,patients
spaCy_R76 spaCy_T76 spaCy_T77 nummod 17,%
spaCy_R77 spaCy_T77 spaCy_T74 appos %,patients
spaCy_R78 spaCy_T78 spaCy_T74 punct ),patients
spaCy_R79 spaCy_T79 spaCy_T79 ROOT experienced,experienced
spaCy_R8 spaCy_T8 spaCy_T9 amod partial,epilepsy
spaCy_R80 spaCy_T80 spaCy_T83 det a,reduction
spaCy_R81 spaCy_T81 spaCy_T82 nummod 75,%
spaCy_R82 spaCy_T82 spaCy_T83 compound %,reduction
spaCy_R83 spaCy_T83 spaCy_T79 dobj reduction,experienced
spaCy_R84 spaCy_T84 spaCy_T83 prep in,reduction
spaCy_R85 spaCy_T85 spaCy_T86 compound seizure,frequency
spaCy_R86 spaCy_T86 spaCy_T84 pobj frequency,in
spaCy_R87 spaCy_T87 spaCy_T84 cc and,in
spaCy_R88 spaCy_T88 spaCy_T84 conj in,in
spaCy_R89 spaCy_T89 spaCy_T92 nummod 8,%
spaCy_R9 spaCy_T9 spaCy_T7 pobj epilepsy,in
spaCy_R90 spaCy_T90 spaCy_T92 punct (,%
spaCy_R91 spaCy_T91 spaCy_T92 nummod 44,%
spaCy_R92 spaCy_T92 spaCy_T88 pobj %,in
spaCy_R93 spaCy_T93 spaCy_T83 punct ),reduction
spaCy_R94 spaCy_T94 spaCy_T95 det the,seizures
spaCy_R95 spaCy_T95 spaCy_T97 nsubjpass seizures,reduced
spaCy_R96 spaCy_T96 spaCy_T97 auxpass were,reduced
spaCy_R97 spaCy_T97 spaCy_T79 conj reduced,experienced
spaCy_R98 spaCy_T98 spaCy_T97 agent by,reduced
spaCy_R99 spaCy_T99 spaCy_T100 advmod at,least